David Z. Qian

5.6k total citations · 2 hit papers
42 papers, 3.7k citations indexed

About

David Z. Qian is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Z. Qian has authored 42 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Molecular Biology, 20 papers in Cancer Research and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Z. Qian's work include Histone Deacetylase Inhibitors Research (13 papers), Cancer, Hypoxia, and Metabolism (11 papers) and Prostate Cancer Treatment and Research (9 papers). David Z. Qian is often cited by papers focused on Histone Deacetylase Inhibitors Research (13 papers), Cancer, Hypoxia, and Metabolism (11 papers) and Prostate Cancer Treatment and Research (9 papers). David Z. Qian collaborates with scholars based in United States, Netherlands and South Africa. David Z. Qian's co-authors include Роберто Пили, Tomasz M. Beer, Peter Atadja, Henk M.W. Verheul, Changhui Xue, Sushant K. Kachhap, Yukihiko Kato, Brenda Salumbides, Michael A. Carducci and Mark Garzotto and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

David Z. Qian

41 papers receiving 3.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth

2008 520 citations David Z. Qian, Hans J. Hammers et al. profile →
Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data

2021 234 citations Duanchen Sun, Xiangnan Guan et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Z. Qian United States	29	2.6k	1.2k	817	785	321	42	3.7k
Caterina Nardella United States	19	3.1k 1.2×	864 0.7×	1.2k 1.5×	896 1.1×	365 1.1×	26	4.2k
Dimpy Koul United States	33	2.6k 1.0×	892 0.7×	877 1.1×	537 0.7×	364 1.1×	63	3.7k
Sarki A. Abdulkadir United States	38	2.6k 1.0×	881 0.7×	1.2k 1.5×	998 1.3×	424 1.3×	93	4.4k
Louis Chesler United Kingdom	35	2.1k 0.8×	1.1k 0.9×	951 1.2×	271 0.3×	322 1.0×	89	3.9k
Leonard Girnita Sweden	36	2.5k 1.0×	898 0.8×	781 1.0×	352 0.4×	216 0.7×	72	3.7k
Oliver Stoeltzing United States	43	3.0k 1.2×	1.4k 1.2×	1.6k 1.9×	538 0.7×	383 1.2×	73	4.6k
John G. Clohessy United States	28	2.9k 1.1×	1.4k 1.2×	756 0.9×	371 0.5×	411 1.3×	50	3.7k
Kristiina Iljin Finland	30	2.1k 0.8×	763 0.6×	767 0.9×	594 0.8×	197 0.6×	56	3.1k
Andrea Morrione United States	40	3.2k 1.2×	866 0.7×	924 1.1×	349 0.4×	307 1.0×	92	4.7k
Gary G. Chiang United States	23	2.9k 1.1×	900 0.8×	666 0.8×	402 0.5×	384 1.2×	47	3.8k

Countries citing papers authored by David Z. Qian

Since Specialization

Citations

This map shows the geographic impact of David Z. Qian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Z. Qian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Z. Qian more than expected).

Fields of papers citing papers by David Z. Qian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Z. Qian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Z. Qian. The network helps show where David Z. Qian may publish in the future.

Co-authorship network of co-authors of David Z. Qian

This figure shows the co-authorship network connecting the top 25 collaborators of David Z. Qian. A scholar is included among the top collaborators of David Z. Qian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Z. Qian. David Z. Qian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xue, Changhui, et al.. (2025). Understanding Enzalutamide‐Resistance Based on a Functional Single‐Cell Approach. The Prostate. 85(9). 888–899.

Sun, Duanchen, Xiangnan Guan, Amy E. Moran, et al.. (2021). Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data. Nature Biotechnology. 40(4). 527–538. 234 indexed citations breakdown →

Li, Yanping, et al.. (2020). Molecular Crosstalk Between MYC and HIF in Cancer. Frontiers in Cell and Developmental Biology. 8. 590576–590576. 66 indexed citations

Zhao, Guisen, Li Zhang, David Z. Qian, Yingxian Sun, & Liu W. (2019). miR-495-3p inhibits the cell proliferation, invasion and migration of osteosarcoma by targeting C1q/TNF-related protein 3. SHILAP Revista de lepidopterología. 4 indexed citations

Geng, Hao, Changhui Xue, Janet Mendonca, et al.. (2018). Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapy. Nature Communications. 9(1). 4972–4972. 54 indexed citations

Liu, Qiong, Hao Geng, Changhui Xue, Tomasz M. Beer, & David Z. Qian. (2015). Functional regulation of hypoxia inducible factor-1α by SET9 lysine methyltransferase. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1853(5). 881–891. 27 indexed citations

Barnett, Christine M., Michael C. Heinrich, Jeong Ho Lim, et al.. (2013). Genetic Profiling to Determine Risk of Relapse-Free Survival in High-Risk Localized Prostate Cancer. Clinical Cancer Research. 20(5). 1306–1312. 19 indexed citations

Liu, Qiong, Chris T. Harvey, Hao Geng, et al.. (2013). Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism. The Prostate. 73(10). 1028–1037. 55 indexed citations

Geng, Hao, Qiong Liu, Changhui Xue, et al.. (2012). HIF1α Protein Stability Is Increased by Acetylation at Lysine 709. Journal of Biological Chemistry. 287(42). 35496–35505. 132 indexed citations

10.

Kachhap, Sushant K., Venkateshwar G. Keshamouni, David Z. Qian, & Aditi Chatterjee. (2011). Cigarette Smoke and Cancer. Journal of Oncology. 2011. 1–2. 2 indexed citations

11.

Пили, Роберто, Brenda Salumbides, Ming Zhao, et al.. (2011). Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. British Journal of Cancer. 106(1). 77–84. 125 indexed citations

12.

Horbinski, Craig, et al.. (2010). Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer. Cancer Research. 70(20). 7992–8002. 288 indexed citations

13.

Geng, Hao, Brooks L. Rademacher, Janét Pittsenbarger, et al.. (2010). ID1 Enhances Docetaxel Cytotoxicity in Prostate Cancer Cells through Inhibition of p21. Cancer Research. 70(8). 3239–3248. 30 indexed citations

14.

Qian, David Z., Catherine O′Brien, Ilsa M. Coleman, et al.. (2009). Prostate Cancer–Associated Gene Expression Alterations Determined from Needle Biopsies. Clinical Cancer Research. 15(9). 3135–3142. 14 indexed citations

15.

Qian, David Z., Brooks L. Rademacher, Janét Pittsenbarger, et al.. (2009). CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel‐induced cytotoxicity. The Prostate. 70(4). 433–442. 93 indexed citations

16.

Verheul, Henk M.W., Brenda Salumbides, Hans J. Hammers, et al.. (2008). Combination Strategy Targeting the Hypoxia Inducible Factor-1α with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors. Clinical Cancer Research. 14(11). 3589–3597. 93 indexed citations

17.

Qian, David Z., et al.. (2007). Antitumor activity of the histone deacetylase inhibitor MS‐275 in prostate cancer models. The Prostate. 67(11). 1182–1193. 53 indexed citations

18.

Verheul, Henk M.W., Martijn P. Lolkema, David Z. Qian, et al.. (2006). Uptake of bevacizumab by platelets blocks the biological activity of platelet-derived vascular endothelial growth factor (VEGF).. Cancer Research. 66. 1342–1343. 3 indexed citations

19.

Qian, David Z., Mingqiang Ren, Xiaofei Wang, et al.. (2005). In vivo imaging of retinoic acid receptor β2 transcriptional activation by the histone deacetylase inhibitor MS‐275 in retinoid‐resistant prostate cancer cells. The Prostate. 64(1). 20–28. 29 indexed citations

20.

Kato, Yukihiko, David Z. Qian, Byungwoo Ryu, et al.. (2004). Restoration of transforming growth factor (TGF) beta signaling pathway in the human prostate carcinoma LNCaP cell line by the histone deacetylase inhibitor MS-275. Cancer Research. 64. 963–963. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact